Desidustat, an oral small molecule that is in phase 2 clinical trial, will help patients suffering from anaemia
Drug firm Zydus Cadila said its oral anaemia developmental candidate, ZYAN1, has been named Desidustat by the World Health Organisation (WHO) INN Committee.
The International Non-proprietary Names (INN) system aims to provide healthcare professionals with a unique and designated name for each pharmaceutical substance, Zydus Group firm Cadila Healthcare said in a filing to the BSE.
Zydus Cadila Chairman Pankaj Patel said, “In keeping with our mission of creating healthier communities globally, it is our constant endeavour to develop therapies that bridge unmet healthcare needs.”
Desidustat, an oral small molecule that is in phase 2 clinical trial, strengthens this commitment with an aim to provide treatment to millions of patients suffering from anaemia, he added.
Two phase I trials of ZYAN1 have been concluded in Australia and India.